FDA places partial hold on Biohaven's ion channel drug
The FDA has placed a troubled Biohaven program on partial clinical hold, the company disclosed Wednesday. An epilepsy study of the experimental drug called BHV-7000 was paused after regulators requested more information about preclinical safety ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
Also reported by 1 other outlet
- FDA places partial hold on Biohaven’s epilepsy drug biopharmadive.com
